Clinical Trials
The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.
Clinical Trials for Kidney Recipients
- Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)
Sponsor: AstraZeneca
Organ Type: All organs
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, January 21, 2025
Other Requirements
- Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Other Requirements
- An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Please refer to https://clinicaltrials.gov/study/NCT04554914 as this is a multi-cohort study which includes options for EBV+ PTLD where standard first-line therapy is inappropriate.
- BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Sponsor: Eledon Pharmaceuticals
Organ Type: Kidney
Ages Accepted: >18 years
Genders Accepted: Both male and female
Expected Study Completion Date: Monday, March 31, 2025
Other Requirements
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)
Sponsor: Hansa Biopharma
Organ Type: Kidney
Ages Accepted: ≥18 and ≤70 years
Genders Accepted: Both male and female
Expected Study Completion Date: December 31, 2023
Other Requirements
- An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies [ARTACUS]
Sponsor: Replimune Inc.
Organ Type: All organs
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: April 30, 2026
Other Requirements:
1. Transplant recipient with stable allograft
2. Diagnosed with locally advanced cutaneous squamous cell carcinoma (CSCC)
3. Local resection or radiation treatment is not a treatment option
4. Has not had prior treatment with an oncolytic therapy
5. There are no metastases in organs or deep tissue
- SAFE KIDNEY II
Sponsor: Memo Therapeutics
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: November 24, 2024
Other Requirements
- A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Sponsor: Novartis
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: July 28, 2026
Other Requirements
Clinical Trials for Other Organ Types
- Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Sponsor: Allovir
Organ Type: All organs
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: Saturday, March 30, 2024
Other Requirements
- Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)
Sponsor: AstraZeneca
Organ Type: All organs
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, January 21, 2025
Other Requirements
- Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Other Requirements
- An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Please refer to https://clinicaltrials.gov/study/NCT04554914 as this is a multi-cohort study which includes options for EBV+ PTLD where standard first-line therapy is inappropriate.
- A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
Sponsor: Novartis
Organ Type: Liver
Ages Accepted: 18 years to 70 years
Genders Accepted: Both male and female
Expected Study Completion Date: April 26, 2023
Other Requirements
- An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies [ARTACUS]
Sponsor: Replimune Inc.
Organ Type: All organs
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: April 30, 2026
Other Requirements:
1. Transplant recipient with stable allograft
2. Diagnosed with locally advanced cutaneous squamous cell carcinoma (CSCC)
3. Local resection or radiation treatment is not a treatment option
4. Has not had prior treatment with an oncolytic therapy
5. There are no metastases in organs or deep tissue